Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
ORGANIZATION
JMA President Confirms Need for Profits from NHI-Market Price Gap
Kichiro Matsumoto, president of the Japan Medical Association (JMA), on September 7 confirmed the need for profits earned by healthcare providers from the gap between drugs’ NHI prices and market prices, sounding negative about any immediate reform on this front.…
To read the full story
Related Article
- FPMAJ-Eyed Overhaul of Price Revision Rules Likely to Curb Price Falls, Cover JP-Listed Meds, Essential Drugs and More
September 9, 2022
- Rapid Removal of NHI-Market Price Gap Will Cause Chaos: Pharmacy Industry Chief
September 9, 2022
- FPMAJ Chief Advocates Drug Price Revision Rule Based on Appropriate Margins for Each Player
September 2, 2022
ORGANIZATION
- JPMA to Set Up Task Force on US MFN Policy, First Meeting Seen This Month
April 21, 2026
- PhRMA Warns Japan Launches Could Erode Global Revenues amid US MFN Policy
April 20, 2026
- JPMA Exec Frets over Material Cost Surge amid Middle East Crisis
April 17, 2026
- JPMA Reshaping Organization to Boost Agility as It Shifts to Legal Entity
April 16, 2026
- JPMA to Launch Nitrosamine Risk Project for APIs in FY2026
April 15, 2026
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s FY2026 drug pricing reform is set to usher in a new phase for the generics market, effectively bringing an…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…